Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million
"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"
Advertisement
Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's TransIT-VirusGEN®, are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for cell and gene therapies.
“This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future. As a leader in the production of viral vectors, our goal is to make the significant potential of cell and gene therapy available for patients worldwide,” said Belén Garijo, Chair of the Executive Board and CEO of Merck. “As a leading science and technology company, we are well-positioned to support our Life Science customers across the biopharmaceutical industry to bring new curative treatments to market.”
“Novel modalities, such as viral vector-based cell and gene therapies, hold immense promise to improve the lives of patients. Combining Mirus Bio's leading technology with Merck's bioprocessing expertise and portfolio allows us to provide solutions for almost every step of viral vector development and manufacturing,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “With our integrated offering along the viral vector value chain, we are now well-positioned to support our customers in this fast-growing market to positively impact the lives and health of patients worldwide.”
“We have been driving innovation in nucleic acid delivery for two decades,” said Dale Gordon, CEO of Mirus Bio. “Merck’s broad portfolio, scale, and global reach, combined with our leading transfection reagents, will help take our business to even greater heights and allow us to serve more customers, and ultimately patients, worldwide.”
The transaction with Gamma Biosciences, a life sciences platform established by global investment firm KKR, for the acquisition of Mirus Bio is expected to close in the third quarter of 2024 and is subject to regulatory clearance and other customary closing conditions.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Last viewed contents
Mayo Clinic researchers map prostate cancer relapse - By using C-11 choline PET and MRI
LDC and Roche will jointly advance innovative drug discovery projects - LDC Enters new Industry Partnership for the Discovery of Novel Medicines
Two colour technique reveals how X-ray lasers damage biomolecules - Step to a fuller understanding of how X-ray flashes modify the structure of proteins
QIAGEN acquires Genoox - "As part of QIAGEN, we can together drive the next wave of precision medicine"
D-Cycloserine Reduces Cocaine-Seeking Behavior in "Addicted" Mice - Antibiotic that appears to control phobias may also be useful in treating addiction
Thermo Fisher Scientific Forms Consortium to Drive Immunotherapy Research Across Europe
Aeras awarded €11.7 million ($16 million) grant from Dutch government
Thermal microscopy of single cells
Using barcodes to trace cell development - Method will facilitate whole new insights into the development of various tissues as well as cancer
Merck Millipore offers quick tests for EHEC in food - Easy to use detection for food manufacturers and researchers
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome - Results Presented at American College of Gastroenterology Annual Meeting Show Majority of Responders Continued to Benefit from GATTEX in Phase 3-Extension Study
